2024
MIF contribution to progressive brain diseases
Matejuk A, Benedek G, Bucala R, Matejuk S, Offner H, Vandenbark A. MIF contribution to progressive brain diseases. Journal Of Neuroinflammation 2024, 21: 8. PMID: 38178143, PMCID: PMC10765708, DOI: 10.1186/s12974-023-02993-6.Peer-Reviewed Original ResearchConceptsBrain diseasesMultiple sclerosisAlzheimer's diseaseMacrophage migration inhibitory factorModulation of neuroinflammationNumerous neurologic diseasesMigration inhibitory factorProgressive brain diseaseNew therapeutic strategiesInflammatory mediatorsChronic inflammationAutoimmune diseasesVascular diseaseNervous system developmentNeurologic diseaseNeuroendocrine functionPsychiatric disordersTherapeutic strategiesEconomic burdenNeurological diseasesNew biomarkersInhibitory factorNeurodegenerative pathologiesDiseaseNovel therapeutics
2023
Bulk and single-nucleus RNA sequencing highlight immune pathways induced in individuals during an Ixodes scapularis tick bite
Tang X, Lynn G, Cui Y, Cerny J, Arora G, Tomayko M, Craft J, Fikrig E. Bulk and single-nucleus RNA sequencing highlight immune pathways induced in individuals during an Ixodes scapularis tick bite. Infection And Immunity 2023, 91: e00282-23. PMID: 37846980, PMCID: PMC10652856, DOI: 10.1128/iai.00282-23.Peer-Reviewed Original ResearchConceptsRNA sequencingSingle-nucleus RNA sequencingBulk RNA sequencingInterleukin-17 signalingPlatelet activation pathwaysLaboratory guinea pigsSnRNA-seqHippo signalingIndividual genesPeripheral bloodTick biteAdaptive immunityAnti-tick vaccinesGuidance pathwayImmune pathwaysNew biomarkersHost responseGuinea pigsHematophagous arthropodsHost defenseCell adhesionTick attachmentNovel insightsTick feedingPhysiological consequencesA subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.
Shaked Y, Benguigui M, Halaban R, Bacchiocchi A, Kamer I, Bar J, Lotem M, Shen-Orr S, Sznol M, Cooper T. A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma. Journal Of Clinical Oncology 2023, 41: 2557-2557. DOI: 10.1200/jco.2023.41.16_suppl.2557.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsCell lung cancerImmunotherapy outcomesImmunotherapy responseMelanoma patientsCancer patientsLung cancerT cellsImmune checkpoint inhibitor-based therapyNew biomarkersNon-small cell lung cancerAdvanced metastatic NSCLCAnti-PD1 responseImmunotherapy-treated patientsMyeloid cell compositionPDL-1 expressionSubset of neutrophilsAnti-PD1 therapyMalignant melanoma patientsBlood mononuclear cellsInhibitor-based therapyPre-clinical modelsRenal cell carcinomaBlood-borne biomarkersSuccessful clinical trials
2021
AACC Guidance Document on Laboratory Investigation of Acute Kidney Injury
El-Khoury JM, Hoenig MP, Jones GRD, Lamb EJ, Parikh CR, Tolan NV, Wilson FP. AACC Guidance Document on Laboratory Investigation of Acute Kidney Injury. The Journal Of Applied Laboratory Medicine 2021, 6: 1316-1337. PMID: 33973621, DOI: 10.1093/jalm/jfab020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute kidney injuryKidney injuryNew biomarkersPotential acute kidney injuryInsulin-like growth factor binding protein 7Growth factor binding protein 7Early detectionLong-term complicationsLaboratory investigationsEmergence of biomarkersHealth care costsBinding protein 7AKI alertsKidney damageClinical indicationsCystatin CSudden episodeCare costsTissue inhibitorDiagnostic thresholdMetalloproteinases 2Test utilizationPreponderance of evidenceTraditional markersExpert recommendationsSoluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis
Carnaru M, Hinchcliff M. Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis. Current Treatment Options In Rheumatology 2021, 7: 21-38. PMID: 40270643, PMCID: PMC12017339, DOI: 10.1007/s40674-021-00171-4.Peer-Reviewed Original ResearchSystemic sclerosisSeverity biomarkersHigh-sensitivity cardiac troponin TSensitivity cardiac troponin TInternal organ involvementPlasma growth factorsNoninvasive screening toolCardiac troponin TDisease biomarkersGI involvementNT-proBNPPulmonary hypertensionCardiac involvementOrgan involvementSerum autoantibodiesEndostatin levelsEndothelial microparticlesHigh morbiditySoluble biomarkersTreatment decisionsCell adhesion moleculeNew biomarkersDisease severityTroponin TDiagnostic testing
2020
Penta-fluorophenol: a Smiles rearrangement-inspired cysteine-selective fluorescent probe for imaging of human glioblastoma
An J, Kang S, Huh E, Kim Y, Lee D, Jo H, Joung J, Kim V, Lee J, Dho Y, Jung Y, Hur J, Park C, Jung J, Huh Y, Ku J, Kim S, Chowdhury T, Park S, Kang J, Oh M, Park C, Kim D. Penta-fluorophenol: a Smiles rearrangement-inspired cysteine-selective fluorescent probe for imaging of human glioblastoma. Chemical Science 2020, 11: 5658-5668. PMID: 32874505, PMCID: PMC7449700, DOI: 10.1039/d0sc01085e.Peer-Reviewed Original ResearchLong-term toxicitySpecific diagnostic proceduresClinical biopsy samplesHuman-derived cellsImmune responseIndividual patientsMouse modelGlioblastoma patientsBiopsy samplesNew biomarkersClinical sitesDisease sitesHuman tissue samplesDiagnostic proceduresGBM cellsHuman glioblastomaTreatment progressTissue samplesClinical samplesCysteine levelsPatientsPrecision diagnosisPresent findingsGBMImaging
2019
Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics
Piersigilli F, Lam TT, Vernocchi P, Quagliariello A, Putignani L, Aghai ZH, Bhandari V. Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics. Metabolomics 2019, 15: 20. PMID: 30830433, DOI: 10.1007/s11306-019-1482-9.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasiaPreterm neonatesNew biomarkersNeonatal intensive care unitMost preterm infantsIntensive care unitNovel specific biomarkersTracheal aspirate samplesSub-group analysisGestational age differencesPreterm infantsCare unitAspirate samplesNeonatesSpecific biomarkersFirst weekC16-OHIsoleucine levelsSelect metabolitesBiomarkersDysplasiaPartial least squares discriminant analysisLeast squares discriminant analysisSquares discriminant analysisAge differences
2016
Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease
Murugesan V, Liu J, Yang R, Lin H, Lischuk A, Pastores G, Zhang X, Chuang WL, Mistry PK. Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. Blood Cells Molecules And Diseases 2016, 68: 47-53. PMID: 28003098, PMCID: PMC5468511, DOI: 10.1016/j.bcmd.2016.12.002.Peer-Reviewed Original ResearchConceptsGaucher diseaseSerum levelsMelanoma BImiglucerase enzyme replacement therapyCohort of patientsEnzyme replacement therapyOverall disease severityGPNMB levelsDisease activityUntreated patientsReplacement therapyDisease miceDisease progressionIndividual patientsLarge cohortHematological diseasesStriking elevationPatientsNew biomarkersDisease pathophysiologyDisease severityDiseaseOrgan compartmentsBiomarkersDisease mechanismsNext-generation molecular diagnosis: single-cell sequencing from bench to bedside
Zhu W, Zhang XY, Marjani SL, Zhang J, Zhang W, Wu S, Pan X. Next-generation molecular diagnosis: single-cell sequencing from bench to bedside. Cellular And Molecular Life Sciences 2016, 74: 869-880. PMID: 27738745, PMCID: PMC11107533, DOI: 10.1007/s00018-016-2368-x.Peer-Reviewed Original ResearchConceptsSingle-cell sequencingSingle gene disordersGenomic medicineMolecular basisCellular heterogeneityChromosomal translocationsSequencingNon-invasive prenatal diagnosisChromosome abnormalitiesTumor cellsDiagnosis/screeningCurrent progressGermlineNew biomarkersTranslocationExciting fieldAneuploidyCellsHigh-resolution studyNext generationIdentificationCEACAM1: Expression and Role in Melanocyte Transformation
Turcu G, Nedelcu RI, Ion DA, Brînzea A, Cioplea MD, Jilaveanu LB, Zurac SA. CEACAM1: Expression and Role in Melanocyte Transformation. Disease Markers 2016, 2016: 9406319. PMID: 27642217, PMCID: PMC5013198, DOI: 10.1155/2016/9406319.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigen cell adhesion molecule 1Melanoma patientsCell adhesion molecule-1Standard immunohistochemical panelImmune checkpoint inhibitorsSubgroup of patientsAdhesion molecule-1Development of melanomaAggressive therapyCheckpoint inhibitorsAdvanced melanomaPoor prognosisMetastatic melanomaImmunohistochemical panelCell adhesion moleculeMelanoma treatmentMolecule-1New biomarkersPatientsMelanoma progressionAdhesion moleculesMelanoma cellsMelanomaNormal melanocytesTherapySerum copeptin in children exposed to maltreatment
Coelho R, Levandowski M, Mansur R, da Cunha G, Asevedo E, Zugman A, Salum G, Gadelha A, Pan P, Rizzo L, Manfro G, Mari J, Rohde L, Miguel E, Bressan R, Brietzke E, Grassi‐Oliveira R. Serum copeptin in children exposed to maltreatment. Psychiatry And Clinical Neurosciences 2016, 70: 434-441. PMID: 27278269, DOI: 10.1111/pcn.12412.Peer-Reviewed Original ResearchConceptsHistory of CMCopeptin levelsSerum copeptinChildhood maltreatmentChild Behavior ChecklistSerum copeptin levelsAdrenal axis activationSerum copeptin concentrationSevere childhood maltreatmentPromising new biomarkerCBCL total scoreEnzyme-linked immunosorbentExternalizing symptomsCopeptin concentrationsSerum levelsAxis activationPsychiatric morbidityPositive historyClinical InterviewCopeptinNew biomarkersHistory of abuseChild psychopathology symptomsSymptom severitySymptomsMultiple sclerosis
Axisa PP, Hafler DA. Multiple sclerosis. Current Opinion In Neurology 2016, 29: 345-353. PMID: 27058221, PMCID: PMC7882195, DOI: 10.1097/wco.0000000000000319.Peer-Reviewed Original ResearchConceptsMultiple sclerosisGenome-wide association studiesAssociation studiesMultiple sclerosis (MS) etiologyMultiple sclerosis progressionMultiple sclerosis patientsHigh-throughput genetic analysisImmune cell functionNumerous candidate biomarkersWide association studyMechanisms of neurodegenerationImmunomodulatory treatmentSclerosis patientsClinical outcomesTreatment arsenalDisease progressionImmune regulationSclerosisNew biomarkersCandidate biomarkersPatient careGenetic variationGenetic analysisCell functionProgressionApplication of new acute kidney injury biomarkers in human randomized controlled trials
Parikh CR, Moledina DG, Coca SG, Thiessen-Philbrook HR, Garg AX. Application of new acute kidney injury biomarkers in human randomized controlled trials. Kidney International 2016, 89: 1372-1379. PMID: 27165835, PMCID: PMC4869991, DOI: 10.1016/j.kint.2016.02.027.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAKI biomarkersKidney injuryClinical trialsNew biomarkersEarly acute kidney injuryObserved relative risk reductionPostoperative acute kidney injuryAcute kidney injury biomarkersHypothetical trialKidney injury progressionMulti-country trialAcute tubular necrosisCardiopulmonary bypass timeClinical risk factorsKidney injury biomarkersProportion of patientsProspective cohort studyKidney injury markersRelative risk reductionAKI progressionAKI trialsBypass timeCohort studyInjury markersPlasma levels of F-actin and F:G-actin ratio as potential new biomarkers in patients with septic shock
Belsky JB, Morris DC, Bouchebl R, Filbin MR, Bobbitt KR, Jaehne AK, Rivers EP. Plasma levels of F-actin and F:G-actin ratio as potential new biomarkers in patients with septic shock. Biomarkers 2016, 21: 180-185. PMID: 26754286, DOI: 10.3109/1354750x.2015.1126646.Peer-Reviewed Original ResearchConceptsSystemic inflammatory response syndromeNoninfectious systemic inflammatory response syndromeSeptic shockThymosin beta 4Healthy controlsSIRS groupPlasma levelsInflammatory response syndromePotential new biomarkersResponse syndromeActin ratioNew biomarkersPotential biomarkersBeta 4PatientsBiomarkersActin levelsF-actinGroupSyndromeLevelsDiagnosis
2015
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? Journal Of Clinical Medicine 2015, 4: 2028-2041. PMID: 26703747, PMCID: PMC4693158, DOI: 10.3390/jcm4121958.Peer-Reviewed Original ResearchMesenchymal transitionAbundant stromal reactionEarly metastatic behaviorPrimary liver cancerEMT-like changesPotential therapeutic targetPro-invasive phenotypeSpecific disease mechanismsDismal prognosisBile ductChronic inflammationEMT biomarkersEpithelial malignanciesStromal reactionLiver cancerTumor stromaTherapeutic targetCholangiocarcinomaNew biomarkersTumor metastatizationMetastatic behaviorCCA cellsTherapeutic opportunitiesTumor microenvironmentStromal cellsThe ongoing quest for biomarkers in Ankylosing Spondylitis
Danve A, O'Dell J. The ongoing quest for biomarkers in Ankylosing Spondylitis. International Journal Of Rheumatic Diseases 2015, 18: 826-834. PMID: 26469363, DOI: 10.1111/1756-185x.12779.Peer-Reviewed Original ResearchConceptsRadiographic progressionC-reactive proteinChronic inflammatory diseaseQuality of lifeDisease activityPotential clinical applicationsHLA-B27Ankylosing SpondylitisDiscovery of biomarkersInflammatory diseasesEarly diagnosisNew biomarkersSpondylitisBiomarkersDisease assessmentClinical applicationProgressionImmunopathogenesisTherapySymptomsDiseaseDiagnosisAutism Spectrum Disorder: Sniffing Out a New Biomarker
Small DM, Pelphrey KA. Autism Spectrum Disorder: Sniffing Out a New Biomarker. Current Biology 2015, 25: r674-r676. PMID: 26241147, DOI: 10.1016/j.cub.2015.06.050.Peer-Reviewed Original Research
2013
Active surveillance in men with low-risk prostate cancer: current and future challenges.
Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. PMID: 25374902, PMCID: PMC4219278.Peer-Reviewed Original ResearchLow-risk prostate cancerActive surveillanceProstate cancerSurvival rateCancer-specific survival ratesProstate-specific antigen (PSA) screeningActive surveillance protocolsCost of overtreatmentActive surveillance programPSA kineticsAntigen screeningSurveillance protocolInstitutional protocolEligibility criteriaMortality rateNew biomarkersCancerSurveillance programLong-term studiesTreatment triggersInterventionMenGenetic testsSurveillanceContemporary reviewIdentification of Novel Predictor Classifiers for Inflammatory Bowel Disease by Gene Expression Profiling
Montero-Meléndez T, Llor X, García-Planella E, Perretti M, Suárez A. Identification of Novel Predictor Classifiers for Inflammatory Bowel Disease by Gene Expression Profiling. PLOS ONE 2013, 8: e76235. PMID: 24155895, PMCID: PMC3796518, DOI: 10.1371/journal.pone.0076235.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseIBD patientsBowel diseaseGene expression profilingGlucocorticoid receptor degradationDegree of inflammationIntestinal inflammationPatients' qualityPinch biopsiesDifferential diagnosisImmune responseEffective treatmentSide effectsClinical practiceExpression profilingNew biomarkersMicroarray gene expression profilingPersonalized approachPatientsPersonalized therapyCurrent markersTranscriptional signatureInter-individual differencesGene expression profilesInflammationBcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients
Pickering CR, Myers JN. Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients. Cancer Discovery 2013, 3: 258-259. PMID: 23475877, DOI: 10.1158/2159-8290.cd-13-0019.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiphenyl CompoundsCarcinoma, Squamous CellCell Cycle ProteinsF-Box ProteinsF-Box-WD Repeat-Containing Protein 7Histone Deacetylase InhibitorsHistone DeacetylasesHumansMyeloid Cell Leukemia Sequence 1 ProteinNitrophenolsPiperazinesProto-Oncogene Proteins c-bcl-2SulfonamidesUbiquitin-Protein Ligases
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply